ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Eli Lilly and Company has tapped Boston biotechnology firm Aktis Oncology to make new radiopharmaceuticals for solid tumors. Lilly will pay Aktis $60 million up front and up to $1.1 billion in milestones to discover the compounds and bring them through preclinical development. Lilly will then be responsible for clinical trials and, if the drug candidates receive approval, commercialization. The companies did not disclose specific targets for the potential medicines.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter